Longitudinal Changes in Asthma Control with Omalizumab: 2-Year Interim Data from the EXCELS Study
Journal of Asthma, 07/27/2012
Eisner MD et al. – Over a 2–year period, patients initiating omalizumab therapy experienced clinically relevant improvements in asthma control, which were maintained during 2 years of longitudinal follow–up. Established users of omalizumab maintained asthma control over the 2–year period with a small improvement similar to that seen in non–omalizumab users.